MAPT and Alzheimer disease: Studies examining the relationship between blood‐based p‐tau217 and both Aβ‐PET and tau‐PET imaging have demonstrated that p‐tau217 levels correspond to both Aβ and tau abnormalities, thereby broadly reflecting AD neuropathological changes (ADNPCs).6, 7, 8, 9, 10, 11